4 transcripts
SDGR
Earnings call transcript
NASDAQ
2024 Q2
31 Jul 24
initial clinical data from this study in the first half of 2025. We plan to present safety pharmacokinetic and pharmacodynamic data as well as preliminary
SDGR
Earnings call transcript
NASDAQ
2024 Q1
1 May 24
objectives of the study are to evaluate the safety tolerability PK/PD and determine the recommended dose, measures of clinical activity are secondary
SDGR
Earnings call transcript
NASDAQ
2023 Q4
28 Feb 24
important insights into the safety and clinical pharmacology of SGR-1505, and this obviates the need to explore food effect and drug-drug interaction
SDGR
Earnings call transcript
NASDAQ
2023 Q2
2 Aug 23
to the insights she will bring.
Turning now to our wholly-owned programs, we are pursuing a global development strategy to build our safety
- Prev
- 1
- Next